Table 1 Data analysis based on 10 clinical trials

From: Quantitative cancer-immunity cycle modeling for predicting disease progression in advanced metastatic colorectal cancer

Group

Number

CR

PR

SD

PD

ORR

DCR

M-OS

TAS-102+Bevacizumab

507

0%

3.9%

58.9%

37.2%

3.9%

62.8%

10.01 months

TAS-102

1486

0%

1.3%

44.4%

54.3%

1.3%

45.7%

7.52 months

Placebo

573

0.2%

0%

15.3%

84.5%

0.2%

15.5%

6.01 months

  1. For each treatment strategy, the clinical indicators CR, PR, SD, and PD are normalized as CR + PR + SD + PD = 1, and ORR = CR + PR, DCR = CR + PR + SD.
Back to article page